The search for a "616 KB" article points directly to a significant medical study titled
: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months. (616 KB)
The study highlighted a few differences between "real-world" patients and those in trials: The search for a "616 KB" article points
: Finding ways to help patients manage side effects so they can stay on the therapy longer. Real-World vs
: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression).
Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you?
